

Table S1. Clinical and pathological characteristics of population in this study

<i>Parameter</i>	<i>Overall patients</i>				<i>Patients with PSA in 4-10</i>			
	All	Positive	Negative	P value	All	Positive	Negative	P value
No.of Patients(%)	292	138(47.26)	154(52.73)		122	37(30.33)	85(69.67)	
Ages				<0.001				0.042
Mean	66.47	68.57	64.58		64.89	67.16	63.89	
SD	7.29	6.13	7.73		8.19	6.10	8.79	
PSA level (ng/ml)				<0.001				0.271
Median	26.65	43.98	11.13		6.57	6.87	6.44	
IQR	7.31-21.93	9.68-49.06	5.92-15.58		5.35-8.16	5.90-8.00	5.32-8.19	
fPSA level (ng/ml)				<0.001				0.156
Median	3.22	4.69	2.07		1.39	1.03	1.55	
IQR	0.97-3.04	1.11-5.80	0.81-2.60		0.71-1.56	0.77-1.30	0.71-1.69	
fPSA/PSA				0.575				0.022
Median	0.21	0.23	0.18		0.18	0.15	0.19	
IQR	0.11-0.21	0.09-0.19	0.12-0.23		0.12-0.22	0.11-0.18	0.13-0.26	
DRE positive				0.007				0.386
No.pts(%)	76(26.02)	46(33.33)	30(19.48)		30(24.59)	11(29.73)	19(22.35)	
Prostate volume (ml)				0.985				0.144
Median	62.55	62.51	62.60		57.35	51.36	60.02	
IQR	34.31-75.12	35.77-79.20	38.80-73.79		33.12-72.10	26.60-69.00	35.40-75.23	

PSAD				<0.001				0.002
Median	0.51	0.82	0.22		0.14	0.18	0.13	
IQR	0.12-0.46	0.22-0.86	0.10-0.27		0.08-0.17	0.08-0.27	0.08-0.15	
Gleason $\leq$ 6		27 (19.57%)				14 (37.84%)		
Gleason=7		59 (42.75%)				17 (48.57%)		
Gleason $\geq$ 8		52 (37.68%)				6 (17.14%)		